Hollings Cancer Center researchers hope to find less toxic, more effective treatment
Mullet were among the fish species studied by researchers at MUSC.
Nathan Dolloff, Ph.D. has been highly active in the University’s innovation pipeline with the submission of multiple records of invention, patent filings, small business grants, and out-licensing of MUSC intellectual property. He is Founder of Leukogene Therapeutics Inc., a startup company focused on commercializing new drugs for the treatment of cancer.
Join us at the Science Café to hear Dr. Michael Yost talk on tissue engineering and 3D bioprinting and how it holds the promise of customized living implants for patients who have lost tissue due to trauma, disease or genetic disability.
Genetic Research Related to Autism Spectrum Disorder (WJCT, Sept., 24, 2018)